Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Inogen, Inc. (INGN) will report Q4 and full year 2023 financial results on February 27, 2024. A conference call and webcast will be hosted the same day. The call will be accessible through dial-in and webcast, with a replay available for three hours after the live webcast ends. Inogen uses its Investor Relations website to disclose material non-public information and comply with disclosure obligations under Regulation FD.
01/30/2024 - 04:00 PM
GOLETA, Calif. --(BUSINESS WIRE)--
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers (877) 841-3961
Non-US callers (201) 689-8589
Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/ . This webcast will also be archived on the website for 6 months.
A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through March 5, 2024. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13743411.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/ , as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/ .
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.
For more information, please visit www.inogen.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130019757/en/
ir@inogen.net
Source: Inogen, Inc.
When will Inogen report Q4 and full year 2023 financial results?
Inogen will report Q4 and full year 2023 financial results after the market closes on Tuesday, February 27, 2024.
How can I listen to the conference call?
Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961, Non-US callers (201) 689-8589. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/.
How long will the webcast be available for replay?
The webcast will be archived on the website for 6 months, with a replay of the call available approximately three hours after the live webcast ends and accessible through March 5, 2024.
What is Inogen's method of disclosing material non-public information?
Inogen uses its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
INGN Rankings
#5337 Ranked by Stock Gains
INGN Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Goleta
About INGN
inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take